SCHEMBL2307429

SCHEMBL2307429

Cc1ccc(Oc2ccc(CC(N)C(=O)O)cc2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.49
ITGA2B P08514 1/20 0.49
PTPN1 P18031 1/20 0.47
KDM4E B2RXH2 2/20 0.47
SLC7A5 Q01650 3/20 0.47
P2RX3 P56373 4/20 0.46
ACACB O00763 5/20 0.46
PTGS1 P23219 2/20 0.45
ALPI P09923 1/20 0.45
PKM P14618 1/20 0.45
XIAP P98170 1/20 0.45
ACACA Q13085 2/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TPH1 P17752 1/20 0.44
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
USP2 O75604 1/20 0.43
EGFR P00533 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2307418 1.00 ITGB3 (0.49) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL2310168 0.86 KDM4E (0.51) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL2310157 0.86 KDM4E (0.51) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL2312907 0.85 ITGB3 (0.49) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL2312094 0.85 LTA4H (0.50) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL2313852 0.85 ITGB3 (0.49) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL2311016 0.85 PCNA (0.49) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL2312099 0.85 LTA4H (0.50) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL2311021 0.85 PCNA (0.49) ITGB3ITGA2BPTPN1KDM4ESLC7A5
SCHEMBL14478230 0.83 SLC7A5 (0.57) ITGB3ITGA2BPTPN1KDM4ESLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288549-B2 Glycine B antagonist MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-16 US disclosed
US-20110190342-A1 GLYCINE B ANTAGONIST HENRICH MARKUS 2011-08-04 US disclosed
EP-2350014-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2011-08-03 EP disclosed
WO-2010037533-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA (DE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190342-A1 GLYCINE B ANTAGONIST GRIN2B, GLRB, GRIN2A ITGB3 4771/4885ITGA2B 4271/4885PTPN1 3936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.